Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168347 · ClinicalTrials.gov registry record · NA
Assessing Patient Confidence in Biologic Medications
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT03168347 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 400 participants.
The verdict
NCT03168347, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
In dermatology, biologic medications are used to treat conditions such as moderate-to-severe psoriasis. These medications generally function to decrease inflammation or disrupt the inflammatory cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (TNF-alpha), blockers/inhibitors (etanercept, infliximab, certolizumab pegol, golimumab), interleukin 12/23 blockers (ustekinumab) and interleukin 17A blockers (secukinumab, ixekizumab). Due to biologic medication's efficacy and safety profiles, they have revolutionized dermatology and the general medical field. However, patients may be apprehensive about choosing a biologic medication for a variety of reasons. These include hearing negative information about the drug from friends or family, being nervous about injection, or seeing the drug or its side effects negatively portrayed in the media. Many patients are not aware that clinical trial evidence for biologics exist, and instead may rely on anecdotal evidence in choosing to take these medications. Because fear of the drug is inherently subjective, it can be modified with appropriate reassurance and presentation of evidence. Physicians must be able to ascertain from where the fear originates and how it can be countered. By understanding what kind of information will allow patients to be confident in their decision to take a biologic, dermatologists can improve outcomes and initiate use of this drug. Furthermore, reducing fear of side effects or adverse events may improve adherence to treatment and may improve treatment outcomes. The investigators propose this study with the goal of learning whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.
Interventions
- BEHAVIORAL Anecdotal Evidence
- BEHAVIORAL Research Study Evidence
- BEHAVIORAL Anecdotal + Research Study Evidence
- BEHAVIORAL No Evidence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2021-06-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168347
The ClinicalTrials.gov registry entry for NCT03168347 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Anecdotal Evidence is the first listed.
NCT03168347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168347 about?
NCT03168347 is a clinical study titled "Assessing Patient Confidence in Biologic Medications". In dermatology, biologic medications are used to treat conditions such as moderate-to-severe psoriasis. These medications generally function to decrease inflammation or disrupt the inflammatory cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (...
What is the current status of trial NCT03168347?
This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2017-06-01. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT03168347?
The interventions under investigation include: Anecdotal Evidence (BEHAVIORAL), Research Study Evidence (BEHAVIORAL), Anecdotal + Research Study Evidence (BEHAVIORAL), No Evidence (BEHAVIORAL).
Who is sponsoring clinical trial NCT03168347?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.